Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.08 -6.6%	$0.24	$0.07 ▼ $1.33	$22M	2.18	48.68 million shs	26.02 million shs
EXOZ eXoZymes	$9.84 -1.7%	$10.90	$8.50 ▼ $23.99	$83.76M	N/A	5,373 shs	1,174 shs
MGX Metagenomi	$1.92	$1.88	$1.23 ▼ $4.92	$71.77M	-0.12	700,950 shs	361,689 shs
VXRT Vaxart	$0.38 -2.7%	$0.44	$0.26 ▼ $1.07	$86.99M	1.12	3.15 million shs	273,111 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+3.36%	+3.36%	-67.19%	-71.63%	-91.78%
EXOZ eXoZymes	0.00%	-0.89%	+0.10%	-23.06%	+1,000,999,900.00%
MGX Metagenomi	-8.57%	-16.52%	+0.52%	+26.73%	-46.07%
VXRT Vaxart	-2.35%	+9.60%	+22.06%	-6.98%	-34.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.5089 of 5 stars	4.0	4.0	0.0	0.0	1.4	0.8	0.0
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	2.6151 of 5 stars	3.5	4.0	0.0	0.0	1.1	1.7	0.6
VXRT Vaxart	3.2792 of 5 stars	3.5	5.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	1,644.09% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A
MGX Metagenomi	3.00	Buy	$13.00	577.08% Upside
VXRT Vaxart	3.00	Buy	$3.00	689.47% Upside

Current Analyst Ratings Breakdown

Latest ADAP, VXRT, EXOZ, and MGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.12	N/A	N/A	$0.05 per share	1.55
EXOZ eXoZymes	$70K	1,176.58	N/A	N/A	$1.25 per share	7.87
MGX Metagenomi	$52.29M	1.37	N/A	N/A	$6.28 per share	0.31
VXRT Vaxart	$47.40M	1.84	N/A	N/A	$0.26 per share	1.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	0.00	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	-$78.06M	-$2.11	0.00	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)
VXRT Vaxart	-$66.95M	-$0.27	N/A	N/A	N/A	-122.63%	-91.89%	-38.40%	8/14/2025 (Estimated)

Latest ADAP, VXRT, EXOZ, and MGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VXRT Vaxart	-$0.08	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	MGX Metagenomi	-$0.62	N/A	N/A	N/A	$7.72 million	N/A
8/11/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.11	N/A	N/A	N/A	$11.04 million	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
5/13/2025	Q1 2025	VXRT Vaxart	-$0.07	-$0.07	N/A	-$0.07	$2.85 million	$20.88 million
5/12/2025	Q1 2025	EXOZ eXoZymes	N/A	-$0.22	N/A	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
EXOZ eXoZymes	N/A	6.52	6.52
MGX Metagenomi	N/A	5.85	5.85
VXRT Vaxart	N/A	0.64	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
EXOZ eXoZymes	N/A
MGX Metagenomi	N/A
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
EXOZ eXoZymes	72.41%
MGX Metagenomi	17.80%
VXRT Vaxart	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
EXOZ eXoZymes	29	8.37 million	2.31 million	N/A
MGX Metagenomi	236	37.38 million	30.73 million	N/A
VXRT Vaxart	120	228.91 million	222.37 million	Optionable

ADAP, VXRT, EXOZ, and MGX Headlines

Recent News About These Companies

Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200-Day Moving Average - Here's Why

August 7 at 5:31 AM | marketbeat.com

Vaxart (VXRT) Expected to Announce Earnings on Thursday

August 7 at 2:30 AM | marketbeat.com

Vaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split Proposal

July 31, 2025 | quiverquant.comQ

Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's Why

July 29, 2025 | marketbeat.com

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

July 24, 2025 | globenewswire.com

Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?

July 19, 2025 | marketbeat.com

Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Here's What Happened

July 11, 2025 | marketbeat.com

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

July 8, 2025 | financialpost.comF

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 | globenewswire.com

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 | globenewswire.com

Vaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025

June 10, 2025 | quiverquant.comQ

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

June 10, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

June 2, 2025 | globenewswire.com

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025 | globenewswire.com

Vaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025

May 29, 2025 | quiverquant.comQ

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025 | globenewswire.com

Vaxart Discusses Reverse Stock Split and Capital Raise

May 28, 2025 | tipranks.com

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025 | globenewswire.com

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman

May 20, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, VXRT, EXOZ, and MGX Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.08 -0.01 (-6.63%)

Closing price 04:00 PM Eastern

Extended Trading

$0.08 +0.00 (+2.97%)

As of 07:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

eXoZymes NASDAQ:EXOZ

$9.84 -0.17 (-1.70%)

As of 01:55 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Metagenomi NASDAQ:MGX

$1.92 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 +0.01 (+0.26%)

As of 07:26 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Vaxart NASDAQ:VXRT

$0.38 -0.01 (-2.71%)

As of 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time